Sutro Biopharma Q4 Earnings Forecast Lifted by HC Wainwright

Sutro Biopharma logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright raised its Q4 2026 EPS estimate to a loss of $1.93 per share from a projected loss of $2.46, while maintaining a Buy rating.
  • Sutro Biopharma’s latest quarter missed expectations: it reported a $1.90-per-share loss versus the consensus loss of $1.64, and revenue of $9.1 million versus estimates of $14.11 million.
  • Analyst sentiment is mostly positive, with a consensus Buy rating and $49.60 target price; shares opened at $9.32 and were down 5.1% in the article’s trading update.
  • Five stocks we like better than Sutro Biopharma.

Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) - Investment analysts at HC Wainwright increased their Q4 2026 earnings estimates for shares of Sutro Biopharma in a note issued to investors on Friday, November 13th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of ($1.93) for the quarter, up from their previous estimate of ($2.46). HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Sutro Biopharma's current full-year earnings is ($8.12) per share. HC Wainwright also issued estimates for Sutro Biopharma's Q3 2027 earnings at ($2.41) EPS, Q4 2027 earnings at ($2.67) EPS, FY2027 earnings at ($9.24) EPS, FY2028 earnings at ($10.87) EPS, FY2029 earnings at ($7.59) EPS and FY2030 earnings at ($7.83) EPS.

Sutro Biopharma (NASDAQ:STRO - Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($1.90) earnings per share for the quarter, missing the consensus estimate of ($1.64) by ($0.26). The firm had revenue of $9.10 million for the quarter, compared to analyst estimates of $14.11 million.

A number of other equities analysts also recently issued reports on the company. Stifel Nicolaus set a $48.00 target price on Sutro Biopharma and gave the stock a "buy" rating in a research note on Friday, August 7th. Wedbush reissued an "outperform" rating and issued a $60.00 price target on shares of Sutro Biopharma in a report on Thursday, October 15th. Barclays lifted their price target on Sutro Biopharma from $56.00 to $57.00 and gave the company an "overweight" rating in a research note on Friday. Wells Fargo & Company began coverage on Sutro Biopharma in a report on Wednesday, September 30th. They set an "overweight" rating and a $49.00 price objective on the stock. Finally, Citizens Jmp cut their price objective on Sutro Biopharma from $41.00 to $34.00 and set a "market outperform" rating for the company in a research report on Thursday, August 13th. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $49.60.

Read Our Latest Stock Report on Sutro Biopharma

Sutro Biopharma Trading Down 5.1%

Shares of STRO opened at $9.32 on Tuesday. Sutro Biopharma has a twelve month low of $7.15 and a twelve month high of $43.85. The stock's 50 day moving average is $12.96 and its two-hundred day moving average is $22.51. The firm has a market capitalization of $154.53 million, a PE ratio of -0.78 and a beta of 1.56.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Wellington Management Group LLP acquired a new stake in shares of Sutro Biopharma during the 2nd quarter valued at approximately $359,000. Sigma Planning Corp acquired a new position in Sutro Biopharma during the first quarter worth $312,000. Jump Financial LLC purchased a new stake in Sutro Biopharma during the third quarter worth $208,000. Bank of America Corp DE boosted its position in Sutro Biopharma by 348.1% during the first quarter. Bank of America Corp DE now owns 18,873 shares of the company's stock worth $470,000 after purchasing an additional 14,661 shares in the last quarter. Finally, Stempoint Capital LP acquired a new stake in Sutro Biopharma in the first quarter valued at $580,000. 96.99% of the stock is currently owned by institutional investors and hedge funds.

More Sutro Biopharma News

These are some of the STRO news items that stood out recently:

  • Positive Sentiment: HC Wainwright raised its price target to $57 and maintained a Buy rating, a potentially supportive signal for the shares. Sutro Biopharma Price Target Raised to $57.00
  • Positive Sentiment: HC Wainwright improved its Q4 2026 EPS estimate to a loss of $1.93 per share from a previously forecast loss of $2.46, indicating a less pessimistic near-term outlook.
  • Negative Sentiment: HC Wainwright cut its full-year EPS forecasts for 2027–2030, projecting larger losses: $9.24 per share for 2027, $10.87 for 2028, $7.59 for 2029 and $7.83 for 2030. These deeper projected losses may temper the positive impact of the target increase.

About Sutro Biopharma

(Get Free Report)

Sutro Biopharma is a biotechnology company focused on discovering and developing targeted cancer treatments. Its research has centered on antibody-drug conjugates (ADCs), which use antibodies to deliver cancer-fighting drugs to selected cells. The company developed its XpressCF+ platform, a cell-free protein synthesis and site-specific conjugation technology intended to support the design and production of biologic medicines. Sutro's clinical-stage programs have included luveltamab tazevibulin, an ADC targeting folate receptor alpha, and STRO-003, an ADC targeting ROR1.

See Also

Earnings History and Estimates for Sutro Biopharma (NASDAQ:STRO)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Sutro Biopharma Right Now?

Before you consider Sutro Biopharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sutro Biopharma wasn't on the list.

While Sutro Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines